COVID-19 Impact on Pulmonary Drug Delivery Devices Market, Global Research Reports 2020-2021

    • ID: AR2933475
    • 27 May, 2020
    • Other
    • Region: Global
    • 103 Pages
    • QYResearch

  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Pulmonary Drug Delivery Devices Industry
  • 1.7 COVID-19 Impact: Pulmonary Drug Delivery Devices Market Trends
  • 2 Global Pulmonary Drug Delivery Devices Quarterly Market Size Analysis

    • 2.1 Pulmonary Drug Delivery Devices Business Impact Assessment - COVID-19
      • 2.1.1 Global Pulmonary Drug Delivery Devices Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
      • 2.1.2 Global Pulmonary Drug Delivery Devices Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Pulmonary Drug Delivery Devices Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 Global Pulmonary Drug Delivery Devices Quarterly Market Size by Manufacturers, 2019 VS 2020
    • 3.2 Global Pulmonary Drug Delivery Devices Factory Price by Manufacturers
    • 3.3 Location of Key Manufacturers Pulmonary Drug Delivery Devices Manufacturing Factories and Area Served
    • 3.4 Date of Key Manufacturers Enter into Pulmonary Drug Delivery Devices Market
    • 3.5 Key Manufacturers Pulmonary Drug Delivery Devices Product Offered
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Pulmonary Drug Delivery Devices Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Dry Powder Inhaler
      • 1.4.2 Metered Dose Inhaler
      • 1.4.3 Nebulizer
    • 4.2 By Type, Global Pulmonary Drug Delivery Devices Market Size, 2019-2021
      • 4.2.1 By Type, Global Pulmonary Drug Delivery Devices Market Size by Type, 2020-2021
      • 4.2.2 By Type, Global Pulmonary Drug Delivery Devices Price, 2020-2021

    5 Impact of Covid-19 on Pulmonary Drug Delivery Devices Segments, By Application

    • 5.1 Overview
      • 5.5.1 Asthma
      • 5.5.2 COPD
      • 5.5.3 Cystic Fibrosis
      • 5.5.4 Other
    • 5.2 By Application, Global Pulmonary Drug Delivery Devices Market Size, 2019-2021
      • 5.2.1 By Application, Global Pulmonary Drug Delivery Devices Market Size by Application, 2019-2021
      • 5.2.2 By Application, Global Pulmonary Drug Delivery Devices Price, 2020-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Boehringer Ingelheim GmbH
      • 7.1.1 Boehringer Ingelheim GmbH Business Overview
      • 7.1.2 Boehringer Ingelheim GmbH Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.1.3 Boehringer Ingelheim GmbH Pulmonary Drug Delivery Devices Product Introduction
      • 7.1.4 Boehringer Ingelheim GmbH Response to COVID-19 and Related Developments
    • 7.2 Novartis AG
      • 7.2.1 Novartis AG Business Overview
      • 7.2.2 Novartis AG Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.2.3 Novartis AG Pulmonary Drug Delivery Devices Product Introduction
      • 7.2.4 Novartis AG Response to COVID-19 and Related Developments
    • 7.3 GlaxoSmithKline
      • 7.3.1 GlaxoSmithKline Business Overview
      • 7.3.2 GlaxoSmithKline Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.3.3 GlaxoSmithKline Pulmonary Drug Delivery Devices Product Introduction
      • 7.3.4 GlaxoSmithKline Response to COVID-19 and Related Developments
    • 7.4 AstraZeneca
      • 7.4.1 AstraZeneca Business Overview
      • 7.4.2 AstraZeneca Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.4.3 AstraZeneca Pulmonary Drug Delivery Devices Product Introduction
      • 7.4.4 AstraZeneca Response to COVID-19 and Related Developments
    • 7.5 Teva Pharmaceutical Industries
      • 7.5.1 Teva Pharmaceutical Industries Business Overview
      • 7.5.2 Teva Pharmaceutical Industries Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.5.3 Teva Pharmaceutical Industries Pulmonary Drug Delivery Devices Product Introduction
      • 7.5.4 Teva Pharmaceutical Industries Response to COVID-19 and Related Developments
    • 7.6 Merck
      • 7.6.1 Merck Business Overview
      • 7.6.2 Merck Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.6.3 Merck Pulmonary Drug Delivery Devices Product Introduction
      • 7.6.4 Merck Response to COVID-19 and Related Developments
    • 7.7 MannKind
      • 7.7.1 MannKind Business Overview
      • 7.7.2 MannKind Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.7.3 MannKind Pulmonary Drug Delivery Devices Product Introduction
      • 7.7.4 MannKind Response to COVID-19 and Related Developments
    • 7.8 Bristol-Myers Squibb
      • 7.8.1 Bristol-Myers Squibb Business Overview
      • 7.8.2 Bristol-Myers Squibb Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.8.3 Bristol-Myers Squibb Pulmonary Drug Delivery Devices Product Introduction
      • 7.8.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
    • 7.9 Mylan N.V
      • 7.9.1 Mylan N.V Business Overview
      • 7.9.2 Mylan N.V Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.9.3 Mylan N.V Pulmonary Drug Delivery Devices Product Introduction
      • 7.9.4 Mylan N.V Response to COVID-19 and Related Developments
    • 7.10 Omron Corp
      • 7.10.1 Omron Corp Business Overview
      • 7.10.2 Omron Corp Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.10.3 Omron Corp Pulmonary Drug Delivery Devices Product Introduction
      • 7.10.4 Omron Corp Response to COVID-19 and Related Developments
    • 7.11 F. Hoffmann-La Roche
      • 7.11.1 F. Hoffmann-La Roche Business Overview
      • 7.11.2 F. Hoffmann-La Roche Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.11.3 F. Hoffmann-La Roche Pulmonary Drug Delivery Devices Product Introduction
      • 7.11.4 F. Hoffmann-La Roche Response to COVID-19 and Related Developments
    • 7.12 3M Healthcare
      • 7.12.1 3M Healthcare Business Overview
      • 7.12.2 3M Healthcare Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.12.3 3M Healthcare Pulmonary Drug Delivery Devices Product Introduction
      • 7.12.4 3M Healthcare Response to COVID-19 and Related Developments
    • 7.13 Sunovion Pharmaceuticals
      • 7.13.1 Sunovion Pharmaceuticals Business Overview
      • 7.13.2 Sunovion Pharmaceuticals Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.13.3 Sunovion Pharmaceuticals Pulmonary Drug Delivery Devices Product Introduction
      • 7.13.4 Sunovion Pharmaceuticals Response to COVID-19 and Related Developments
    • 7.14 Koninklijke Philips N.V
      • 7.14.1 Koninklijke Philips N.V Business Overview
      • 7.14.2 Koninklijke Philips N.V Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.14.3 Koninklijke Philips N.V Pulmonary Drug Delivery Devices Product Introduction
      • 7.14.4 Koninklijke Philips N.V Response to COVID-19 and Related Developments
    • 7.15 Gerresheimer AG
      • 7.15.1 Gerresheimer AG Business Overview
      • 7.15.2 Gerresheimer AG Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.15.3 Gerresheimer AG Pulmonary Drug Delivery Devices Product Introduction
      • 7.15.4 Gerresheimer AG Response to COVID-19 and Related Developments
    • 7.16 Bespak
      • 7.16.1 Bespak Business Overview
      • 7.16.2 Bespak Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.16.3 Bespak Pulmonary Drug Delivery Devices Product Introduction
      • 7.16.4 Bespak Response to COVID-19 and Related Developments
    • 7.17 AptarGroup
      • 7.17.1 AptarGroup Business Overview
      • 7.17.2 AptarGroup Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.17.3 AptarGroup Pulmonary Drug Delivery Devices Product Introduction
      • 7.17.4 AptarGroup Response to COVID-19 and Related Developments
    • 7.18 SHL Group
      • 7.18.1 SHL Group Business Overview
      • 7.18.2 SHL Group Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.18.3 SHL Group Pulmonary Drug Delivery Devices Product Introduction
      • 7.18.4 SHL Group Response to COVID-19 and Related Developments
    • 7.19 Nypro Healthcare
      • 7.19.1 Nypro Healthcare Business Overview
      • 7.19.2 Nypro Healthcare Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.19.3 Nypro Healthcare Pulmonary Drug Delivery Devices Product Introduction
      • 7.19.4 Nypro Healthcare Response to COVID-19 and Related Developments
    • 7.20 Hovione
      • 7.20.1 Hovione Business Overview
      • 7.20.2 Hovione Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.20.3 Hovione Pulmonary Drug Delivery Devices Product Introduction
      • 7.20.4 Hovione Response to COVID-19 and Related Developments
    • 7.21 Chiesi Farmaceutici S.P.A
      • 7.21.1 Chiesi Farmaceutici S.P.A Business Overview
      • 7.21.2 Chiesi Farmaceutici S.P.A Pulmonary Drug Delivery Devices Quarterly Production and Revenue, 2020
      • 7.21.3 Chiesi Farmaceutici S.P.A Pulmonary Drug Delivery Devices Product Introduction
      • 7.21.4 Chiesi Farmaceutici S.P.A Response to COVID-19 and Related Developments

    8 Supply Chain and Sales Channels Analysis

    • 8.1 Pulmonary Drug Delivery Devices Supply Chain Analysis
      • 8.1.1 Pulmonary Drug Delivery Devices Supply Chain Analysis
      • 8.1.2 Covid-19 Impact on Pulmonary Drug Delivery Devices Supply Chain
    • 8.2 Distribution Channels Analysis
      • 8.2.1 Pulmonary Drug Delivery Devices Distribution Channels
      • 8.2.2 Covid-19 Impact on Pulmonary Drug Delivery Devices Distribution Channels
      • 8.2.3 Pulmonary Drug Delivery Devices Distributors
    • 8.3 Pulmonary Drug Delivery Devices Customers

    9 Key Findings

      10 Appendix

      • 10.1 About Us

      This report covers market size and forecasts of Pulmonary Drug Delivery Devices, including the following market information:
      Global Pulmonary Drug Delivery Devices Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Pulmonary Drug Delivery Devices Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Pulmonary Drug Delivery Devices Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units)
      Global Pulmonary Drug Delivery Devices Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)

      Key market players
      Major competitors identified in this market include Boehringer Ingelheim GmbH, Novartis AG, GlaxoSmithKline, AstraZeneca, Teva Pharmaceutical Industries, Merck, MannKind, Bristol-Myers Squibb, Mylan N.V, Omron Corp, F. Hoffmann-La Roche, 3M Healthcare, Sunovion Pharmaceuticals, Koninklijke Philips N.V, Gerresheimer AG, Bespak, AptarGroup, SHL Group, Nypro Healthcare, Hovione, Chiesi Farmaceutici S.P.A, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Dry Powder Inhaler
      Metered Dose Inhaler
      Nebulizer

      Based on the Application:
      Asthma
      COPD
      Cystic Fibrosis
      Other



      Summary:
      Pulmonary Drug Delivery Devices Market Research Report is about Pulmonary Drug Delivery Devices Industry study. Get complete Pulmonary Drug Delivery Devices market research report published after Market Study, Industrial Analysis with Trends & Statistics. Pulmonary Drug Delivery Devices Market Report is a syndicated report for Investors and Manufacturer to understand Market Demand, Growth, trends and Factor Influencing market in upcoming years.



      REPORT YOU MIGHT BE INTERESTED